A number of research firms have changed their ratings and price targets for Nektar Therapeutics (NASDAQ: NKTR):
- 10/12/2026 – Nektar Therapeutics is now covered by UBS Group. They set a “neutral” rating and a $53.00 price target on the stock.
- 10/12/2026 – Nektar Therapeutics was upgraded by UBS Group to “hold”.
- 10/12/2026 – Nektar Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $130.00 price target on the stock.
- 10/9/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
- 10/9/2026 – Nektar Therapeutics is now covered by Raymond James Financial. They set a “market perform” rating on the stock.
- 10/2/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $185.00 price target on the stock.
- 9/25/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
- 9/23/2026 – Nektar Therapeutics had its price target lowered by Wedbush from $80.00 to $50.00. They now have a “neutral” rating on the stock.
- 9/16/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
- 9/9/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
Insider Transactions at Nektar Therapeutics
In related news, CEO Howard Robin sold 418 shares of Nektar Therapeutics stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $71.98, for a total transaction of $30,087.64. Following the completion of the transaction, the chief executive officer directly owned 54,627 shares of the company’s stock, valued at $3,932,051.46. This trade represents a 0.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.50% of the stock is owned by corporate insiders.
Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines for autoimmune, inflammatory and other serious diseases. The company uses its proprietary biologics and polymer-conjugation technologies to design therapies intended to improve immune-system regulation, drug activity and dosing convenience.
Nektar’s pipeline includes rezpegaldesleukin, an investigational treatment designed to expand regulatory T cells and potentially restore immune tolerance in conditions such as atopic dermatitis, alopecia areata and other autoimmune diseases.
Read More
- Five stocks we like better than Nektar Therapeutics
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
